Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded the related topic 'Non-alcoholic fatty liver disease' to the study page and updated the revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check15 days agoChange DetectedRemoved related topics: 'Non-alcoholic fatty liver disease' and 'MedlinePlus Genetics' from the related topics section.SummaryDifference0.0%

- Check22 days agoChange DetectedAdded related topics: Non-alcoholic fatty liver disease and MedlinePlus Genetics to the page.SummaryDifference0.0%

- Check29 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; this is a minor update that does not affect the page content or its primary functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check36 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedGlossary is now shown and the page revision is updated to v3.4.0. A new field 'Last Update Submitted that Met QC Criteria' is displayed, while older terms such as 'No FEAR Act data' and 'MedlinePlus Genetics' are removed and QC wording updated.SummaryDifference0.1%

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.